Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS with Rosuvastatin [LUNAR] Trial)

American Journal of Cardiology

Volumn 111, Issue 4, 2013, Pages 506-509

  Ballantyne, Christie M ^a   Pitt, Bertram ^b   Loscalzo, Joseph ^c   Cain, Valerie A ^d   Raichlen, Joel S ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE CORONARY SYNDROME; AGED; APOLIPOPROTEINS B; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84873315682     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.10.037     Document Type: Article

References (8)

1. J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, D.E. Casey Jr., W.E. Chavey II, F.M. Fesmire, J.S. Hochman, T.N. Levin, A.M. Lincoff, E.D. Peterson, P. Theroux, N.K. Wenger, and R.S. Wright ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
2. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr., N.J. Stone Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
3. Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, and D. Wood ESC/EAS guidelines for the management of dyslipidaemias Eur Heart J 32 2011 1769 1818
4. J.D. Brunzell, M. Davidson, C.D. Furberg, R.B. Goldberg, B.V. Howard, J.H. Stein, and J.L. Witztum Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524
5. B. Pitt, J. Loscalzo, J. Ycas, and J.S. Raichlen Lipid levels after acute coronary syndromes J Am Coll Cardiol 51 2008 1440 1445
6. B. Pitt, J. Loscalzo, J. Monyak, M. Miller, and J. Raichlen Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study) Am J Cardiol 109 2012 1239 1246
7. A.D. Sniderman, C.D. Furberg, A. Keech, J.E. Roeters van Lennep, J. Frohlich, I. Jungner, and G. Walldius Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 2003 777 780
8. C.M. Ballantyne, J.S. Raichlen, and V.A. Cain Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY) trial J Am Coll Cardiol 52 2008 626 632